IDEXX jumps about 20% after third-quarter beat and raised 2026 outlook

IDEXX Laboratories shares surged about 20% Monday after the veterinary diagnostics company topped third-quarter earnings and revenue estimates and raised its 2026 forecasts. The company reported third-quarter revenue of $1.21 billion, about 10% above the year-earlier period, driven by growth in its Companion Animal Group.

Follow live markets on X @therealapdult.

CNBC's midday movers desk flagged the print as one of the session's standout earnings reactions. Separate market tallies put quarterly sales at $1,214 million and described adjusted earnings of $3.96 per share, ahead of a consensus estimate of $3.73. Management also lifted full-year 2026 revenue guidance and raised the earnings outlook while lowering its operating-margin outlook.

The stock ranked among the largest percentage gainers on major U.S. exchanges on the day, with one tape snapshot near $663. Investors rewarded the combination of a clean beat, recurring diagnostics growth, and a higher guide — even with the softer margin commentary.

Monday's tape otherwise mixed earnings winners and losers: Tempus AI rose nearly 12% after its own third-quarter beat, while several smaller names that missed or guided softly sold off. IDEXX's move stood apart for both size and liquidity.

Near-term, watch whether follow-through holds as analysts refresh models on the new guide, and whether Companion Animal utilization trends stay firm into year-end. For a one-day tape read, this was a classic high-quality beat-and-raise re-rating in a defensive growth name.